Role of cannabinoid receptors and RAGE in inflammatory bowel disease

Histology and Histopathology

Volumn 26, Issue 6, 2011, Pages 735-745

  Stintzing, Sebastian ^a   Wissniowski, Till Th ^b   Lohwasser, Christina ^b   Alinger, Beate ^c   Neureiter, Daniel ^c   Ocker, Matthias ^b,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

CNR1; CNR2; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; ENTERITIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 79959862125     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Basta G. (2008). Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 196, 9-21.
2. Becker C., Fantini M.C. and Neurath M.F. (2006). TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev. 17, 97-106.
3. Bouma G. and Strober W. (2003). The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533.
4. Boussac M. and Garin J. (2000). Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 21, 665-672.
5. Breese E.J., Michie C.A., Nicholls S.W., Murch S.H., Williams C.B., Domizio P., Walker-Smith J.A. and MacDonald T.T. (1994). Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106, 1455-1466.
6. Casu M.A., Porcella A., Ruiu S., Saba P., Marchese G., Carai M.A., Reali R., Gessa G.L. and Pani L. (2003). Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur. J. Pharmacol 459, 97-105.
7. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K. and Pagotto U. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431.
8. D'Argenio G., Valenti M., Scaglione G., Cosenza V., Sorrentini I. and Di Marzo V. (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20, 568-570.
9. Dammeier J., Brauchle M., Falk W., Grotendorst G.R. and Werner S. (1998). Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int. J. Biochem. Cell Biol. 30, 909-922.
10. Darmani N.A. and Johnson J.C. (2004). Central and peripheral mechanisms contribute to the antiemetic actions of delta-9- tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur. J. Pharmacol. 488, 201-212.
11. Di Marzo V. and Izzo A.A. (2006). Endocannabinoid overactivity and intestinal inflammation. Gut 55, 1373-1376.
12. Duncan M., Mouihate A., Mackie K., Keenan C.M., Buckley N.E., Davison J.S., Patel K.D., Pittman Q.J. and Sharkey K.A. (2008). Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am. J. Physiol. Gastrointest Liver Physiol. 295, G78-G87.
13. Foell D., Kucharzik T., Kraft M., Vogl T., Sorg C., Domschke W. and Roth J. (2003). Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52, 847-853.
14. Gahr S., Peter G., Wissniowski T.T., Hahn E.G., Herold C. and Ocker M. (2008). The histone-deacetylase inhibitor MS-275 and the CDK- inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol. Rep. 20, 1249-1256.
15. Guagnini F., Valenti M., Mukenge S., Matias I., Bianchetti A., Di Palo S., Ferla G., Di Marzo V. and Croci T. (2006). Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55, 946-953.
16. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I. and Mechoulam R. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662-3665.
17. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D. and Schmidt A.M. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901.
18. Iborra M., Bernuzzi F., Invernizzi P. and Danese S. (2010). MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response. Autoimmun Rev. (in press).
19. Izzo A.A. (2007). The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 19, 704-708.
20. Izzo A.A. and Camilleri M. (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57, 1140-1155.
21. Izzo A.A. and Camilleri M. (2009). Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 60, 117-125.
22. Izzo A.A., Fezza F., Capasso R., Bisogno T., Pinto L., Iuvone T., Esposito G., Mascolo N., Di Marzo V. and Capasso F. (2001). Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134, 563-570.
23. Klein T.W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5, 400-411.
24. Kulkarni-Narla A. and Brown D.R. (2000). Localization of CB1- cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res. 302, 73-80.
25. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., D'Argenio G., Scaglione G., Bifulco M., Sorrentini I. and Di Marzo V. (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687.
26. Lohwasser C., Neureiter D., Popov Y., Bauer M. and Schuppan D. (2009). Role of the receptor for advanced glycation end products in hepatic fibrosis. World J. Gastroenterol. 15, 5789-5798.
27. Lu D., Vemuri V.K., Duclos R.I. Jr and Makriyannis A. (2006). The cannabinergic system as a target for anti-inflammatory therapies. Curr. Top. Med. Chem. 6, 1401-1426.
28. Lunn C.A., Reich E.P. and Bober L. (2006). Targeting the CB2 receptor for immune modulation. Expert. Opin. Ther. Targets 10, 653-663.
29. Mannon P.J., Fuss I.J., Dill S., Friend J., Groden C., Hornung R., Yang Z., Yi C., Quezado M., Brown M. and Strober W. (2006). Excess IL- 12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology 131, 748-756.
30. Marquart S., Zerr P., Akhmetshina A., Palumbo K., Reich N., Tomcik M., Horn A., Dees C., Engel M., Zwerina J., Distler O., Schett G. and Distler J.H. (2010). Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 62, 3467-3476.
31. Marquez L., Suarez J., Iglesias M., Bermudez-Silva F.J., Rodriguez de Fonseca F. and Andreu M. (2009). Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One 4, e6893.
32. Massa F. and Monory K. (2006). Endocannabinoids and the gastrointestinal tract. J. Endocrinol. Invest. 29, 47-57.
33. Massa F., Marsicano G., Hermann H., Cannich A., Monory K., Cravatt B.F., Ferri G.L., Sibaev A., Storr M. and Lutz B. (2004). The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209.
34. Mendez-Sanchez N., Zamora-Valdes D., Pichardo-Bahena R., Barredo-Prieto B., Ponciano-Rodriguez G., Bermejo-Martinez L., Chavez-Tapia N.C., Baptista-Gonzalez H.A. and Uribe M. (2007). Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int. 27, 215-219.
35. Miligi L., Costantini A.S., Benvenuti A., Kriebel D., Bolejack V., Tumino R., Ramazzotti V., Rodella S., Stagnaro E., Crosignani P., Amadori D., Mirabelli D., Sommani L., Belletti I., Troschel L., Romeo L., Miceli G., Tozzi G.A., Mendico I. and Vineis P. (2006). Occupational exposure to solvents and the risk of lymphomas. Epidemiology 17, 552-561.
36. Monteleone G., Del Vecchio Blanco G., Monteleone I., Fina D., Caruso R., Gioia V., Ballerini S., Federici G., Bernardini S., Pallone F. and MacDonald T.T. (2005). Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology 129, 1420-1429.
37. Neureiter D., Zopf S., Leu T., Dietze O., Hauser-Kronberger C., Hahn E.G., Herold C. and Ocker M. (2007). Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand. J. Gastroenterol. 42, 103-116.
38. Patel K.D., Davison J.S., Pittman Q.J. and Sharkey K.A. (2010) Cannabinoid CB(2) receptors in health and disease. Curr. Med. Chem. 17, 1393-1410.
39. Quint K., Stintzing S., Alinger B., Hauser-Kronberger C., Dietze O., Gahr S., Hahn E.G., Ocker M. and Neureiter D. (2009). The expression pattern of PDX-1, SHH, Patched and Gli-1 is associated with pathological and clinical features in human pancreatic cancer. Pancreatology 9, 116-126.
40. Rajesh M., Mukhopadhyay P., Batkai S., Hasko G., Liaudet L., Huffman J.W., Csiszar A., Ungvari Z., Mackie K., Chatterjee S. and Pacher P. (2007). CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293, H2210-2218.
41. Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P. and Raedler A. (1993). Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94, 174-181.
42. Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Knuechel R., Baeuerle P.A., Scholmerich J. and Gross V. (1998). Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357-369.
43. Samson M.T., Small-Howard A., Shimoda L.M., Koblan-Huberson M., Stokes A.J. and Turner H. (2003). Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J. Immunol. 170, 4953-4962.
44. Sanger G.J. (2007). Endocannabinoids and the gastrointestinal tract: what are the key questions? Br. J. Pharmacol. 152, 663-670.
45. Schmidt A.M., Yan S.D., Yan S.F. and Stern D.M. (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955.
46. Shepherd N.A., Jass J.R., Duval I., Moskowitz R.L., Nicholls R.J. and Morson B.C. (1987). Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J. Clin. Pathol. 40, 601-607.
47. Sonkoly E. and Pivarcsi A. (2009). Advances in microRNAs: implications for immunity and inflammatory diseases. J. Cell Mol. Med. 13, 24-38.
48. Steffens S. and Mach F. (2006). Cannabinoid receptors in atherosclerosis. Curr. Opin. Lipidol. 17, 519-526.
49. Storr M.A., Keenan C.M., Emmerdinger D., Zhang H., Yuce B., Sibaev A., Massa F., Buckley N.E., Lutz B., Goke B., Brand S., Patel K.D. and Sharkey K.A. (2008). Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med. 86, 925-936.
50. Storr M.A., Keenan C.M., Zhang H., Patel K.D., Makriyannis A. and Sharkey K.A. (2009). Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm. Bowel Dis. 15, 1678-1685.
51. Strober W., Fuss I. and Mannon P. (2007). The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521.
52. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., Nguyen M., Olsson A., Nawroth P.P., Bierhaus A., Varki N., Kronenberg M., Freeze H.H. and Srikrishna G. (2008). RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29, 2035-2043.
53. Wacnik P.W., Luhr K.M., Hill R.H., Ljunggren H.G., Kristensson K. and Svensson M. (2008). Cannabinoids affect dendritic cell (DC) potassium channel function and modulate DC T cell stimulatory capacity. J. Immunol. 181, 3057-3066.
54. Wright K., Rooney N., Feeney M., Tate J., Robertson D., Welham M. and Ward S. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129, 437-453.
55. Wright K.L., Duncan M. and Sharkey K.A. (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br. J. Pharmacol. 153, 263-270.
56. Zen K., Chen C.X., Chen Y.T., Wilton R. and Liu Y. (2007). Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J. Immunol. 178, 2483-2490.